CellBiotech: Regulating the Gut to Save the Kidneys, the 'Miracle' of the Gut-Kidney Axis Revealed by 'K-Probiotics'
Predicted impact: Low
Probiotic research feature; the same Duolac research was already covered recently.
Cell Biotech쎌바이오텍
049960 · KOSDAQ · ₩049960 · 쎌바이오텍
₩14,830▼ ₩80 (0.54%)End-of-day · Oct 28, 2026 · End-of-day prices.
CellBiotech's Duolac: CBT Probiotic Shown to Improve Chronic Kidney Disease Mechanism
Predicted impact: Low
Probiotic mechanism research; early-stage with no disclosed financial impact.
Also known as: Cell Biotech / 쎌바이오텍 / 049960 / KRX:049960
Source: KRX statistical information